Berenberg has slashed Grifols' target price by 23% to 19.8 euros due to higher-than-expected net debt. Despite this, Berenberg remains optimistic about Grifols' potential, estimating a...
Grifols reports positive results from its Phase IV study of Fanhdi for von Willebrand disease (VWD) treatment, showing safety and efficacy. Presented at the 2024 World...
Grifols leads the IBEX 35's mid-morning gains, rising 3.42% to 9.02 euros, marking its fourth consecutive positive day. Despite falling over 40% for the year, the...
The Spanish pharma sector faced a downturn in the stock market in Q1 of 2024, with a collective market capitalization drop of 15.8% for six listed...
Europacific Growth Fund, legal owner of Grifols shares, lent over 100 million euros worth of shares, reducing its ownership from 3.4% to 3.2%. Capital Research and...
BlackRock, Capital Research and Management Company, and Jefferies Financial Group lend over 170 million euros in Grifols shares. Specifically, BlackRock, which has a 4.3% stake in...
The main European stock markets opened this Wednesday with mixed trends. Specifically, Paris and London lost 0.1% and 0.05%, respectively, while Milan and Frankfurt rose 0.16%...
Grifols' guidance for 2024 estimates recording an adjusted EBITDA of more than 1.8 billion euros, as well as a free cash flow of five million euros....
Of the Spanish pharma listed companies, PharmaMar has suffered the most significant drop in profits due to generic drug competition with its star drug. Rovi has...
This counterattack by Gotham comes weeks after Grifols has received accolades following the confirmation of the sale to Haier of its 20% stake in Shanghai Raas...